Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Bina Kamble"'
Autor:
Ali Elgalib, Samir Shah, Zeyana Al-Habsi, Maha Al-Fouri, Halima Al-Sawafi, Jalila Al-Noumani, Adil Al-Baloushi, Saad Al-Alawi, Salma Al-Badi, Zainab Mohammed, Jokha Al-Ghafri, Asma Suleimani, Huda Al-Mashani, Jyothish Raju, Saada Al-Riyami, Muna Al-Shukri, Abdul Wahab, Bilal Hussain, Khalifa Al-Naabi, Anantha Narayan, Noreen Oliveros, George Prasad, Ahmed Hussein, Rajeev Kashyp, Khalid Al-Shardi, Ahmed Nada, Shakil Akhwand, Bina Kamble, Kawthar Al-Aamri, Suad Al-Mukhaini, Hanan Al-Kindi, Faryal Khamis, Amal Al-Maani, Idris Al-Abaidani, Seif Al-Abri
Publikováno v:
International Journal of Infectious Diseases, Vol 71, Iss C, Pp 94-99 (2018)
Objective: To assess the impact of capacity-building interventions introduced by the Oman National AIDS Programme on the quality of HIV care in the country. Methods: HIV viral load (VL) suppression and loss to follow-up (LTFU) rates were calculated f
Externí odkaz:
https://doaj.org/article/78d053dbe5ba451c8706796687fcac80
Publikováno v:
Sultan Qaboos University Medical Journal, Vol 17, Iss 3, Pp 339-342 (2017)
Ritonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other drugs that are metabolised via the CYP3A4 pa
Externí odkaz:
https://doaj.org/article/7c0b7626d5294daa903befbe40c24fa2
Autor:
Thamra Al Ghafri, Bina Kamble, Mustafa Al Shaaibi, Sultan Al Lawati, Ruwaida Al Ismaili, Nasser Al Kindi, Salim Al Qasabi, Magdi Al Osali, Hamad Al Harthi, Saud Al Harthi, Mohammed Alhinai
Publikováno v:
Cureus
Background and objective Coronavirus disease 2019 (COVID-19) has become a public health emergency of international concern. Several characteristics of hospitalised cases, including variations in symptoms as well as radiological and laboratory finding
Autor:
Saud Al Harthi, Magdi AlOsali, Ruwaida Al Ismaili, Sultan Al Lawati, Bina Kamble, Mustafa Al Shaaibi, Nasser Al kindi, Salim Al Qasabi, Mohamed Al Hinai, Hamad Al Harthi, Thamra Al Ghafri
Background: With the coronavirus disease 19 (COVID-19) pervading the world, little has been published regarding the hospitalized cases of COVID-19 (confirmed) in the Arabian Gulf countries. This paper describes the socio-demographic, clinical, labora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e748b54e581457d58206b2c444aa5a73
https://doi.org/10.21203/rs.3.rs-39988/v1
https://doi.org/10.21203/rs.3.rs-39988/v1
Autor:
Faryal Khamis, Adil Al-Baloushi, Ali Elgalib, Zainab Mohammed, Kawthar Al-Aamri, Halima Al-Sawafi, Jyothish Raju, Ahmed Nada, Zeyana Al-Habsi, Hanan Al-Kindi, Samir S. Shah, Bina Kamble, Noreen Oliveros, Saad Al-Alawi, Abdul Wahab, George Prasad, Idris Al-Abaidani, Shakil Akhwand, Maha Al-Fouri, Khalifa Al-Naabi, Saada Al-Riyami, Suad Al-Mukhaini, Khalid Al-Shardi, Anantha Narayan, Ahmed Hussein, Rajeev Kashyp, Jokha Al-Ghafri, Salma Al-Badi, Bilal Hussain, Seif Al-Abri, Jalila Al-Noumani, Amal Al-Maani, Huda N. Al-Mashani, Muna Al-Shukri, Asma Suleimani
Publikováno v:
International Journal of Infectious Diseases, Vol 71, Iss C, Pp 94-99 (2018)
Objective: To assess the impact of capacity-building interventions introduced by the Oman National AIDS Programme on the quality of HIV care in the country. Methods: HIV viral load (VL) suppression and loss to follow-up (LTFU) rates were calculated f
Publikováno v:
AIDS Care. 30:1114-1119
Multidisciplinary team (MDT) care models have been shown to improve clinical outcomes among HIV patients. We aim to assess the impact of adopting MDT approach in a tertiary HIV clinic in Muscat, Sultanate of Oman. We introduced MDT approach in our HI
Publikováno v:
Sultan Qaboos University Medical Journal, Vol 17, Iss 3, Pp 339-342 (2017)
Ritonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other drugs that are metabolised via the CYP3A4 pa